G-protein inactivator RGS6 mediates myocardial cell apoptosis and cardiomyopathy caused by doxorubicin

Cancer Research

Volumn 73, Issue 6, 2013, Pages 1662-1667

  Yang, Jianqi ^a   Maity, Biswanath ^a   Huang, Jie ^a   Gao, Zhan ^a   Stewart, Adele ^a   Weiss, Robert M ^a   Anderson, Mark E ^a   Fisher, Rory A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CASPASE 3; DOXORUBICIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MDM2; PROTEIN P53; RGS PROTEIN; RGS6 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG TISSUE LEVEL; ENZYME ACTIVATION; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SURVIVAL TIME; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARDIOMYOPATHIES; DOXORUBICIN; GTP-BINDING PROTEINS; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; REACTIVE OXYGEN SPECIES; RGS PROTEINS;

EID: 84875475071     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3453     Document Type: Article

References (20)

1. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
2. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008;26:3777-84.
3. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-79.
4. Mertens AC, Yasui Y, Neglia JP, Potter JD, Nesbit ME Jr, Ruccione K, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001;19:3163-72.
5. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-82.
6. Erickson JR, He BJ, Grumbach IM, Anderson ME. CaMKII in the cardiovascular system: sensing redox states. Physiol Rev 2011;91: 889-915.
7. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996;335:1182-9.
8. Hare JM. Oxidative stress and apoptosis in heart failure progression. Circ Res 2001;89:198-200.
9. Shizukuda Y, Matoba S, Mian OY, Nguyen T, Hwang PM. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Mol Cell Biochem 2005;273:25-32.
10. Liu X, Chua CC, Gao J, Chen Z, Landy CL, Hamdy R, et al. Pifithrinalpha protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice. Am J Physiol Heart Circ Physiol 2004;286: H933-9.
11. Maity B, Yang J, Huang J, Askeland RW, Bera S, Fisher RA. Regulator of G protein signaling 6 (RGS6) induces apoptosis via a mitochondrialdependent pathway not involving its GTPase-activating protein activity. J Biol Chem 2011;286:1409-19.
12. Huang J, Yang J, Maity B, Mayuzumi D, Fisher RA. Regulator of G protein signaling 6 mediates doxorubicin-induced ATM and p53 activation by a reactive oxygen species-dependent mechanism. Cancer Res 2011;71:6310-9.
13. Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radical Biol Med 2010;48:749-62.
14. Yang J, Huang J, Maity B, Gao Z, Lorca RA, Gudmundsson H, et al. RGS6, a modulator of parasympathetic activation in heart. Circ Res 2010;107:1345-9.
15. Neilan TG, Blake SL, Ichinose F, Raher MJ, Buys ES, Jassal DS, et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation 2007;116:506-14.
16. Mukhopadhyay P, Rajesh M, Batkai S, Kashiwaya Y, Hasko G, Liaudet L, et al. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin- induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol 2009;296:H1466-83.
17. Maya R, Balass M, Kim ST, Shkedy D, Leal JF, Shifman O, et al. ATMdependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev 2001;15:1067-77.
18. Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y, Shkedy D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. PNAS 1999;96:14973-7.
19. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol 2011;301:H2181-90.
20. Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT. ATM activation by oxidative stress. Science 2010;330:517-21.